ArticleEnvironmental health perspectives2020
Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of Guinea-Bissau Children.
Article in Environmental health perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Childhood PFAS exposure and immunotoxicity: a systematic review and meta-analysis of human studies.Systematic reviews · 2024Pooled it
- Pediatric effects of forever chemicals may last for a long time.Pediatric research · 2026Review
- In Utero Per- and Polyfluoroalkyl Substances (PFAS) Exposure and Changes in Infant T Helper Cell Development among UPSIDE-ECHO Cohort Participants.Environmental health perspectives · 2026Article
- Associations of prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and childhood vaccine-induced immunity.Environmental health : a global access science source · 2026Article
- Association between perfluoroalkyl and polyfluoroalkyl substances and response to the COVID-19 vaccine in a paediatric prospective observational cohort in Arizona.BMJ paediatrics open · 2026Observational
- A Network Toxicology Framework for Identification of Immune System Disruption by Per- and Polyfluoroalkyl Substance (PFAS) Mixture: In Silico Analysis.Journal of xenobiotics · 2026Article
- Associations of mid-childhood per- and polyfluoroalkyl substances and early childhood metals with mid-childhood antibody titers.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- Early-Life Exposures, Neurodevelopment, and Health Outcomes: Protocol for a Birth Cohort Study.JMIR research protocols · 2026Article
- Models and challenges for studying forever chemicals and their impact on human health.Disease models & mechanisms · 2025Review
- Evaluation and comparison of tools used to quantify aggregate PFAS exposure: Extractable organic fluorine, PFAS burden scores and summed PFAS concentrations.Journal of exposure science & environmental epidemiology · 2025Article
- Review
- Maternal exposure to per- and polyfluoroalkyl substances and epitope level antibody response to vaccines against measles and rubella in children from the Boston birth cohort.Environment international · 2025Article
- Decoding PFAS immunotoxicity: a NAMs-based comparison of short vs. long chains.Frontiers in toxicology · 2025Article
- Cross-cutting studies of per- and polyfluorinated alkyl substances (PFAS) in Arctic wildlife and humans.The Science of the total environment · 2024Review
- Review
- Article
- Association between family economic situation and serum PFAS concentration in American adults with hypertension and hyperlipemia.Scientific reports · 2024Article
- Contributions of Synthetic Chemicals to Autoimmune Disease Development and Occurrence.Current environmental health reports · 2024Review
- Altered Transcriptome Response in PBMCs of Czech Adults Linked to Multiple PFAS Exposure: B Cell Development as a Target of PFAS Immunotoxicity.Environmental science & technology · 2024Article
- Neonatal per- and polyfluoroalkyl substance exposure in relation to retinoblastoma.Environmental research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundPerfluoroalkyl substances (PFAS) are a group of widely used persistent chemicals with suspected immunotoxic effects.
objectivesThe present study aimed to examine the association between infant PFAS exposure and antibody responses to measles vaccination as well as morbidity in a low-income country.
methodsIn a randomized controlled trial, children from Guinea-Bissau, West Africa, were followed from inclusion (4-7 months of age) through 2 years of age. Half the children received two measles vaccinations (at inclusion and at 9 months of age), and the other half received only one (at 9 months of age). In a subset of 237 children, six PFAS were quantified in serum at inclusion, and measles antibody concentrations were assessed at inclusion and at approximately 9 months and 2 years of age. At inclusion and at the 9-month visit, mothers were interviewed about infant morbidity.
resultsAll but one child had detectable serum concentrations of all six PFAS, although levels were lower than seen elsewhere. A doubling in perfluorooctane sulfonic acid (PFOS) and perfluorodecanoic acid (PFDA) were associated with 21% (95% CI: 2, 37%) and 25% (95% CI: 1, 43%), respectively, lower measles antibody concentrations at the 9-month visit among the children who had received a measles vaccine at inclusion. Elevated serum PFAS concentrations were also associated with reduced prevaccination measles antibody concentrations and increased morbidity. DISCUSSION: The present study documents that PFAS exposure has reached West Africa and that infants show PFAS-associated increases in morbidity and decreases in measles-specific antibody concentrations before and after vaccination. These findings support the evidence on PFAS immunotoxicity at comparatively low serum concentrations. https://doi.org/10.1289/EHP6517.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.